LOTENSIN (benazepril hydrochloride) by Bausch Health is angiotensin-converting enzyme (ace) in human subjects and animals. First approved in 1991.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
Lotensin (benazepril hydrochloride) is an oral ACE inhibitor approved in 1991 for hypertension management. It works by inhibiting angiotensin-converting enzyme, reducing angiotensin II production and decreasing vasopressor activity and aldosterone secretion. The drug is effective across renin-angiotensin profiles and maintains efficacy even in low-renin hypertension patients.
Lotensin faces LOE with moderate competitive pressure (30/100), signaling contraction of brand team infrastructure and shift toward generic support roles.
angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does benazepril. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions
Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting Conditions
Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Worked on LOTENSIN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Lotensin offers limited career growth opportunities as a legacy ACE inhibitor approaching loss of exclusivity with zero linked job postings. Employment trajectory favors operational, compliance, and generic transition roles over brand-building, sales, or innovation-focused positions.